Drugs / TKM-080301
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01437007 | Aug 2011 → Jun 2012 | breast cancer, colorectal cancer, gastric cancer, ovarian cancer +1 | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT02191878 | Jun 2014 → May 2016 | adult hepatocellular carcinoma | Arbutus Biopharma Corporation | Completed | No outcome recorded |
| Phase 1/2 | NCT01262235 | Dec 2010 → Jul 2015 | adrenal cortex carcinoma, neuroendocrine neoplasm | Arbutus Biopharma Corporation | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TKM080301 | “Participants will have a liver angiogram (type of X-ray study) to look at the blood flow in the liver and to place a catheter for delivery of the TKM080301.” NCT01437007 ↗ |
| Action | Inhibit | “Inhibition of PLK1 activity in proliferating cancer cells rapidly induces mitotic arrest and apoptosis.” NCT01437007 ↗ |
| Modality | Small interfering RNA (siRNA) | “containing siRNA” NCT01437007 ↗ |
| Route | Intravenous | “Repeat dose IV infusion.” NCT01262235 ↗ |
| Target | PLK1 | “siRNA against the PLK1 (polo-like kinase-1) gene product” NCT01437007 ↗ |